VANCOUVER--(BUSINESS WIRE)--Zymeworks Inc., a privately held computational biotechnology company, today announced it has entered into a research agreement with California-based XOMA Ltd. (Nasdaq: XOMA, www.xoma.com) to optimize an undisclosed antibody using Zymeworks’ ZymeCAD™ suite of predictive protein engineering tools and XOMA’s innovative Targeted Affinity Enhancement™ (TAE™) technology for antibody mutagenesis and optimization. Financial terms are not disclosed.
